Market Overview:
The global glucocorticoid for systemic lupus erythematosus market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of systemic lupus erythematosus, rising awareness about the disease, and growing demand for glucocorticoids for treating SLE. Based on type, the global glucocorticoid for systemic lupus erythematosus market is segmented into hydrocortisone, prednisone, prednisolone, triamcinolone acetonide, dexamethasone, betamethasone and other types. Prednisolone is expected to be the fastest-growing type during the forecast period from 2018 to 2030. This can be attributed to its high efficacy in treating SLE and its wide availability as a generic drug.
Product Definition:
A glucocorticoid is a steroid hormone that is produced in the adrenal cortex. Glucocorticoids are important for systemic lupus erythematosus because they help to reduce inflammation.
Hydrocortisone:
Lupus Erythematosus (LE) is a chronic, systemic autoimmune disorder affecting the skin, joints, and/or kidneys. It is estimated that 1-2% of the global population suffers from LE. The disease has an incidence rate of 2-3 per 100000 people annually in North America and Europe.
Prednison:
The drug prednison is used in the treatment of rheumatoid arthritis, osteoarthritis and lupus. It works by decreasing the production of cytokines (chemicals that trigger inflammation). The drug has been approved by FDA for usage in Systemic Lupus Erythematosus (SLE) but it has not been approved for use as a glucocorticoid.
Application Insights:
The other application segment includes nasal sprays, ointments, creams and oral gels. Hydrocortisone is the most commonly used glucocorticoid for systemic lupus erythematosus in clinics and hospitals due to its high solubility property. However, corticosteroids are generally not preferred for use in clinics as they can have adverse effects on a patient's health depending upon the dosage and duration of intake.
Hydrocortisone is also one of the most widely used drugs across all applications owing to its low price coupled with high efficiency as well as due to availability in generic forms. Prednisolone is another drug that finds widespread usage across various applications owing to its faster action than hydrocortisone along with fewer side effects when compared with other glucocorticoids such as prednisolONE or prednisONE or triamcinolONE acetonide (dexamethasone).
Regional Analysis:
North America dominated the global glucocorticoid market in 2017. The region is expected to witness a CAGR of XX% over the forecast period, owing to high prevalence of systemic lupus erythematosus (SLE) and increasing healthcare expenditure in countries such as U.S., Canada, and Mexico.
Asia Pacific is expected to be one of the fastest-growing regions during the forecast period due to rising awareness about available treatments for SLE among patients & physicians.
Growth Factors:
- Increasing incidence of systemic lupus erythematosus (SLE)
- Growing awareness about SLE and its treatment options
- Rising demand for better and more effective therapies for SLE patients
- Availability of novel glucocorticoid drugs with improved safety and efficacy profiles
- Growing number of clinical studies on glucocorticoids for the treatment of SLE
Scope Of The Report
Report Attributes
Report Details
Report Title
Glucocorticoid for Systemic Lupus Erythematosus Market Research Report
By Type
Hydrocortisone, Prednison, Prednisolone, Triamcinolone Acetonide, Dexamethasone, Betamethasone, Other
By Application
Hospital, Clinic, Pharmacy, Other
By Companies
Pfizer, Sanofi, Teva, Akorn, GSK, Bausch and Lomb, Bayer Pharmas, Fougera Pharms, Hikma Intl Pharms, Impax Labs, Lannett, Merck, Novartis, Sandoz, TARO, Valeant, Wockhardt, Solvay Pharma, Alcon, Paladin Labs, Adcock Ingram, ADARE Pharmaceuticals, Aspen Holdings, Astellas Pharma, Endo International, Sun Pharmaceutical, Perrigo, Aerosol
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
141
Number of Tables & Figures
99
Customization Available
Yes, the report can be customized as per your need.
Global Glucocorticoid for Systemic Lupus Erythematosus Market Report Segments:
The global Glucocorticoid for Systemic Lupus Erythematosus market is segmented on the basis of:
Types
Hydrocortisone, Prednison, Prednisolone, Triamcinolone Acetonide, Dexamethasone, Betamethasone, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Sanofi
- Teva
- Akorn
- GSK
- Bausch and Lomb
- Bayer Pharmas
- Fougera Pharms
- Hikma Intl Pharms
- Impax Labs
- Lannett
- Merck
- Novartis
- Sandoz
- TARO
- Valeant
- Wockhardt
- Solvay Pharma
- Alcon
- Paladin Labs
- Adcock Ingram
- ADARE Pharmaceuticals
- Aspen Holdings
- Astellas Pharma
- Endo International
- Sun Pharmaceutical
- Perrigo
- Aerosol
Highlights of The Glucocorticoid for Systemic Lupus Erythematosus Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hydrocortisone
- Prednison
- Prednisolone
- Triamcinolone Acetonide
- Dexamethasone
- Betamethasone
- Other
- By Application:
- Hospital
- Clinic
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glucocorticoid for Systemic Lupus Erythematosus Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glucocorticoids are medications that help to reduce inflammation and swelling. Systemic lupus erythematosus (SLE) is an autoimmune disease in which the body's immune system attacks its own tissues. Glucocorticoids can help to reduce the symptoms of SLE, including inflammation, pain, and swelling.
Some of the major companies in the glucocorticoid for systemic lupus erythematosus market are Pfizer, Sanofi, Teva, Akorn, GSK, Bausch and Lomb, Bayer Pharmas, Fougera Pharms, Hikma Intl Pharms, Impax Labs, Lannett, Merck, Novartis, Sandoz, TARO, Valeant, Wockhardt, Solvay Pharma, Alcon, Paladin Labs, Adcock Ingram, ADARE Pharmaceuticals, Aspen Holdings, Astellas Pharma, Endo International, Sun Pharmaceutical, Perrigo, Aerosol.
The glucocorticoid for systemic lupus erythematosus market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glucocorticoid for Systemic Lupus Erythematosus Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glucocorticoid for Systemic Lupus Erythematosus Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glucocorticoid for Systemic Lupus Erythematosus Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glucocorticoid for Systemic Lupus Erythematosus Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glucocorticoid for Systemic Lupus Erythematosus Market Size & Forecast, 2018-2028
4.5.1 Glucocorticoid for Systemic Lupus Erythematosus Market Size and Y-o-Y Growth
4.5.2 Glucocorticoid for Systemic Lupus Erythematosus Market Absolute $ Opportunity
Chapter 5 Global Glucocorticoid for Systemic Lupus Erythematosus Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Type
5.2.1 Hydrocortisone
5.2.2 Prednison
5.2.3 Prednisolone
5.2.4 Triamcinolone Acetonide
5.2.5 Dexamethasone
5.2.6 Betamethasone
5.2.7 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Glucocorticoid for Systemic Lupus Erythematosus Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Pharmacy
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glucocorticoid for Systemic Lupus Erythematosus Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Glucocorticoid for Systemic Lupus Erythematosus Analysis and Forecast
9.1 Introduction
9.2 North America Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Type
9.6.1 Hydrocortisone
9.6.2 Prednison
9.6.3 Prednisolone
9.6.4 Triamcinolone Acetonide
9.6.5 Dexamethasone
9.6.6 Betamethasone
9.6.7 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Pharmacy
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Glucocorticoid for Systemic Lupus Erythematosus Analysis and Forecast
10.1 Introduction
10.2 Europe Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Type
10.6.1 Hydrocortisone
10.6.2 Prednison
10.6.3 Prednisolone
10.6.4 Triamcinolone Acetonide
10.6.5 Dexamethasone
10.6.6 Betamethasone
10.6.7 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Pharmacy
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Glucocorticoid for Systemic Lupus Erythematosus Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Type
11.6.1 Hydrocortisone
11.6.2 Prednison
11.6.3 Prednisolone
11.6.4 Triamcinolone Acetonide
11.6.5 Dexamethasone
11.6.6 Betamethasone
11.6.7 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Pharmacy
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Glucocorticoid for Systemic Lupus Erythematosus Analysis and Forecast
12.1 Introduction
12.2 Latin America Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Type
12.6.1 Hydrocortisone
12.6.2 Prednison
12.6.3 Prednisolone
12.6.4 Triamcinolone Acetonide
12.6.5 Dexamethasone
12.6.6 Betamethasone
12.6.7 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Pharmacy
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Glucocorticoid for Systemic Lupus Erythematosus Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Type
13.6.1 Hydrocortisone
13.6.2 Prednison
13.6.3 Prednisolone
13.6.4 Triamcinolone Acetonide
13.6.5 Dexamethasone
13.6.6 Betamethasone
13.6.7 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Glucocorticoid for Systemic Lupus Erythematosus Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Pharmacy
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glucocorticoid for Systemic Lupus Erythematosus Market: Competitive Dashboard
14.2 Global Glucocorticoid for Systemic Lupus Erythematosus Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Sanofi
14.3.3 Teva
14.3.4 Akorn
14.3.5 GSK
14.3.6 Bausch and Lomb
14.3.7 Bayer Pharmas
14.3.8 Fougera Pharms
14.3.9 Hikma Intl Pharms
14.3.10 Impax Labs
14.3.11 Lannett
14.3.12 Merck
14.3.13 Novartis
14.3.14 Sandoz
14.3.15 TARO
14.3.16 Valeant
14.3.17 Wockhardt
14.3.18 Solvay Pharma
14.3.19 Alcon
14.3.20 Paladin Labs
14.3.21 Adcock Ingram
14.3.22 ADARE Pharmaceuticals
14.3.23 Aspen Holdings
14.3.24 Astellas Pharma
14.3.25 Endo International
14.3.26 Sun Pharmaceutical
14.3.27 Perrigo
14.3.28 Aerosol
